|
1
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5(66)2019.
|
|
2
|
Dogan N and Toprak D: Female breast cancer
mortality rates in Turkey. Asian Pac J Cancer Prev. 15:7569–7573.
2014.
|
|
3
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sauter ER: Reliable biomarkers to identify
new and recurrent cancer. Eur J Breast Health. 13:162–167.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhao Z and Shilatifard A: Epigenetic
modifications of histones in cancer. Genome Biol. 20(245)2019.
View Article : Google Scholar
|
|
6
|
Miller JL and Grant PA: The role of DNA
methylation and histone modifications in transcriptional regulation
in humans. Subcell Biochem. 61:289–317. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang Y and Jia S: Degrees make all the
difference: The multifunctionality of histone H4 lysine 20
methylation. Epigenetics. 4:273–276. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Svobodová Kovaříková A, Legartová S,
Krejčí J and Bártová E: H3K9me3 and H4K20me3 represent the
epigenetic landscape for 53BP1 binding to DNA lesions. Aging
(Albany NY). 10:2585–2605. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jørgensen S, Schotta G and Sørensen CS:
Histone H4 lysine 20 methylation: Key player in epigenetic
regulation of genomic integrity. Nucleic Acids Res. 41:2797–2806.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tryndyak VP, Kovalchuk O and Pogribny IP:
Loss of DNA methylation and histone H4 lysine 20 trimethylation in
human breast cancer cells is associated with aberrant expression of
DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and
methyl-binding proteins. Cancer Biol Ther. 5:65–70. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yokoyama Y, Matsumoto A, Hieda M, Shinchi
Y, Ogihara E, Hamada M, Nishioka Y, Kimura H, Yoshidome K,
Tsujimoto M and Matsuura N: Loss of histone H4K20 trimethylation
predicts poor prognosis in breast cancer and is associated with
invasive activity. Breast Cancer Res. 16(R66)2014.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
van Nuland R and Gozani O: Histone H4
lysine 20 (H4K20) methylation, expanding the signaling potential of
the proteome one methyl moiety at a time. Mol Cell Proteomics.
15:755–764. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fraga MF, Ballestar E, Villar-Garea A,
Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S,
Petrie K, et al: Loss of acetylation at Lys16 and trimethylation at
Lys20 of histone H4 is a common hallmark of human cancer. Nat
Genet. 37:391–400. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Füllgrabe J, Kavanagh E and Joseph B:
Histone onco-modifications. Oncogene. 30:3391–3403. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sakabe K, Wang Z and Hart GW:
Beta-N-acetylglucosamine (O-GlcNAc) is part of the histone code.
Proc Natl Acad Sci USA. 107:19915–19920. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
West AC and Johnstone RW: New and emerging
HDAC inhibitors for cancer treatment. J Clin Investig. 124:30–39.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Shanmugam MK, Arfuso F, Arumugam S,
Chinnathambi A, Jinsong B, Warrier S, Wang LZ, Kumar AP, Ahn KS,
Sethi G and Lakshmanan M: Role of novel histone modifications in
cancer. Oncotarget. 19:11414–11426. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Noberini R, Osti D, Miccolo C, Richichi C,
Lupia M, Corleone G, Hong SP, Colombo P, Pollo B, Fornasari L, et
al: Extensive and systematic rewiring of histone post-translational
modifications in cancer model systems. Nucleic Acids Res.
46:3817–3832. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Simpson NE, Tryndyak VP, Beland FA and
Pogribny IP: An in vitro investigation of metabolically sensitive
biomarkers in breast cancer progression. Breast Cancer Res Treat.
133:959–968. 2012. View Article : Google Scholar
|
|
20
|
Shinchi Y, Hieda M, Nishioka Y, Matsumoto
A, Yokoyama Y, Kimura H, Matsuura S and Matsuura N: SUV420H2
suppresses breast cancer cell invasion through down regulation of
the SH2 domain-containing focal adhesion protein tensin-3. Exp Cell
Res. 334:90–99. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ (eds): WHO classification of tumours of the
breast. In: WHO Classification of Tumours. Vol 4. 4th edition.
IARC, Lyon. 2012.
|
|
22
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Singletary SE, Allred C, Ashley P, Bassett
LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, et
al: Revision of the American Joint Committee on Cancer staging
system for breast cancer. J Clin Oncol. 20:3628–3636.
2002.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Viotti M, Wilson C, McCleland M, Koeppen
H, Haley B, Jhunjhunwala S, Klijn C, Modrusan Z, Arnott D, Classon
M, et al: SUV420H2 is an epigenetic regulator of
epithelial/mesenchymal states in pancreatic cancer. J Cell Biol.
217:763–777. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Elsheikh SE, Green AR, Rakha EA, Powe DG,
Ahmed RA, Collins HM, Soria D, Garibaldi JM, Paish CE, Ammar AA, et
al: Global histone modifications in breast cancer correlate with
tumor phenotypes, prognostic factors, and patient outcome. Cancer
Res. 69:3802–3809. 2009.PubMed/NCBI View Article : Google Scholar
|
